Compare Amylx Pharmaceuticals Inc (AMLX) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Wheaton Precious Metals Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Wheaton Precious Metals Corp trades at $109.68 (market cap $49.85B). The key difference: Wheaton Precious Metals Corp is far larger — about 25.2× Amylx Pharmaceuticals Inc's market cap, and Wheaton Precious Metals Corp pays a 0.71% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | WPM | |
|---|---|---|
Market Cap | $1.98B | $49.85B |
Sector | Health | Basic Materials |
52-Week High | $18.70 | $165.72 |
52-Week Low | $7.64 | $88.32 |
Enterprise Value | $1.70B | $47.69B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Wheaton Precious Metals (WPM) trades at $110.05, down 0.54% on the day, amid a bearish technical signal. The company exhibits strong fundamentals with 2025 revenue of $2.31B, net income of $1.47B, and consistent earnings beats. Analyst consensus is strongly bullish with a $163 price target, though recent news highlights sensitivity to precious metal price volatility.
WPM offers a compelling growth story with robust profitability and positive cash flow, but faces risks from commodity price swings and acquisition integration. The stock's current discount to analyst targets presents a potential opportunity for long-term investors, contingent on stable metal prices and execution of production outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
